Evidence map›Paper›PMID 42445110›Full record

ReviewBMJ oncology2026

Future of radiotheranostics.

Akram Al-Ibraheem, Serin Moghrabi, Raghad Mohammad Al-Houwari, Soud Al-Qasem, Marwah Abdulrahman, Nouraldeen Alzorgan, Louai Sohil Al-Qatawna, Qais Al-Hammouri, Mohammad Ghanameh, Saad Ruzzeh and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMJ oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Akram Al-IbraheemNuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan.ORCID https://orcid.org/0000-0002-0978-4716
Serin MoghrabiNuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan.
Raghad Mohammad Al-HouwariNuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan.
Soud Al-QasemNuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan.
Marwah AbdulrahmanNuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan.
Nouraldeen AlzorganNuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan.
Louai Sohil Al-QatawnaNuclear Medicine Department, Jordanian Royal Medical Services, Amman, Jordan.
Qais Al-HammouriDepartment of Medicine, Jordanian Royal Medical Services, Amman, Jordan.ORCID https://orcid.org/0009-0006-5177-3371
Mohammad GhanamehSchool of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Saad RuzzehNuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan.
Ahmed Saad AbdlkadirNuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotheranostics is reshaping precision oncology by integrating molecular imaging with targeted radionuclide therapy through matched diagnostic-therapeutic radiopharmaceutical pairs. Landmark clinical successes, including Lutetium-177-DOTATATE (

Indexed as

Medical oncologyReceptorsSolid tumourSurvival AnalysisTumour biomarkers

Identifiers

PMID42445110
PMCPMC13358243

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.